Skip to main content
no upcoming events

Please check back with us.

Trial Spotlight

FORAGER-1; NCT05614739

A Phase 1, Open-label, Multicenter Study of LY3866288 (LOXO-435) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer with FGFR3 Alterationsa

See Trial
Filter our pipeline to find information relevant to you. Search results will appear below.
Recruiting

Breast

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
CDK4/6 Inhibitor
Abemaciclib
NCT02107703; MONARCH 2
3
Active, not recruiting
CDK4/6 Inhibitor
Abemaciclib
NCT02246621; MONARCH 3
3
Active, not recruiting
CDK4/6 Inhibitor
Abemaciclib
NCT03155997; monarchE
3
Active, not recruiting
CDK4/6 Inhibitor
Abemaciclib
NCT05169567; postMONARCH
3
Active, not recruiting
FRα Antibody-Drug Conjugate
LY4170156
NCT06400472
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 1
LY4101174
NCT06238479; EXCEED
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 2
LY4052031
NCT06465069; NEXUS-01
1
Active, not recruiting
Pan-Mutant Selective PI3Kα Inhibitor
LY4064809 (STX-478)
NCT05768139
1
Recruiting
Selective Estrogen Receptor Degrader
Imlunestrant
NCT04188548; EMBER
1
Active, not recruiting
Selective Estrogen Receptor Degrader
Imlunestrant
NCT04975308; EMBER-3
3
Active, not recruiting
Selective Estrogen Receptor Degrader
Imlunestrant
NCT05514054; EMBER-4
3
Recruiting

Gastrointestinal

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
FRα Antibody-Drug Conjugate
LY4170156
NCT06400472
1
Recruiting
KRAS G12C Inhibitor
Olomorasib
NCT04956640
2
Recruiting
KRAS G12D Inhibitor
LY3962673
NCT06586515; MOONRAY-01
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 1
LY4101174
NCT06238479; EXCEED
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 2
LY4052031
NCT06465069; NEXUS-01
1
Active, not recruiting
Pan-KRAS Inhibitor
LY4066434
NCT06607185
1
Recruiting

Genitourinary

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
FGFR3 Inhibitor
LY3866288
NCT05614739; FORAGER-1
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 1
LY4101174
NCT06238479; EXCEED
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 2
LY4052031
NCT06465069; NEXUS-01
1
Active, not recruiting
Prostate-Specific Membrane Antigen (PSMA) Radioligand
[Ac-225]-PSMA-62
NCT06229366; ACCEL
1
Recruiting

Gynecologic

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
FRα Antibody-Drug Conjugate
LY4170156
NCT06400472
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 1
LY4101174
NCT06238479; EXCEED
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 2
LY4052031
NCT06465069; NEXUS-01
1
Active, not recruiting
Selective Estrogen Receptor Degrader
Imlunestrant
NCT04188548; EMBER
1
Active, not recruiting

Hematologic

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
BAFF-R T-Cell Engager
LY4152199
PRECLINICAL
BTK Inhibitor
Pirtobrutinib
NCT03740529; BRUIN
2
Active, not recruiting
BTK Inhibitor
Pirtobrutinib
NCT04662255; BRUIN MCL-321
3
Active, not recruiting
BTK Inhibitor
Pirtobrutinib
NCT04666038; BRUIN CLL-321
3
Active, not recruiting
BTK Inhibitor
Pirtobrutinib
NCT04965493; BRUIN CLL-322
3
Active, not recruiting
BTK Inhibitor
Pirtobrutinib
NCT05023980; BRUIN CLL-313
3
Active, not recruiting
BTK Inhibitor
Pirtobrutinib
NCT05254743; BRUIN CLL-314
3
Active, not recruiting

Lung

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
FRα Antibody-Drug Conjugate
LY4170156
NCT06400472
1
Recruiting
KRAS G12C Inhibitor
Olomorasib
NCT04956640
2
Recruiting
KRAS G12C Inhibitor
Olomorasib
NCT06119581; SUNRAY-01
3
Recruiting
KRAS G12C Inhibitor
Olomorasib
NCT06890598; SUNRAY-02
3
Recruiting
KRAS G12D Inhibitor
LY3962673
NCT06586515; MOONRAY-01
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 1
LY4101174
NCT06238479; EXCEED
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 2
LY4052031
NCT06465069; NEXUS-01
1
Active, not recruiting
Pan-KRAS Inhibitor
LY4066434
NCT06607185
1
Recruiting
PTK7 Antibody-Drug Conjugate
LY4175408
PRECLINICAL
RET Inhibitor
Selpercatinib
NCT04194944; LIBRETTO-431
3
Active, not recruiting
RET Inhibitor
Selpercatinib
NCT04819100; LIBRETTO-432
3
Active, not recruiting
SMARCA2 (BRM) Inhibitor
LY4050784
NCT06561685
1
Recruiting
VEGF Receptor-2 Antagonist
Ramucirumab
NCT02411448; RELAY
3
Active, not recruiting

Other Solid Tumors

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
177Lu-FAP
LY4337713
PRECLINICAL
CDK4/6 Inhibitor
Abemaciclib
NCT04238819
2
Active, not recruiting
CDK4/6 Inhibitor
Abemaciclib
NCT06413706
2
Recruiting
FGFR3 Inhibitor
LY3866288
NCT05614739; FORAGER-1
1
Recruiting
KRAS G12C Inhibitor
Olomorasib
NCT04956640
2
Recruiting
KRAS G12D Inhibitor
LY3962673
NCT06586515; MOONRAY-01
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 1
LY4101174
NCT06238479; EXCEED
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 2
LY4052031
NCT06465069; NEXUS-01
1
Active, not recruiting
Pan-KRAS Inhibitor
LY4066434
NCT06607185
1
Recruiting
Pan-Mutant Selective PI3Kα Inhibitor
LY4064809 (STX-478)
NCT05768139
1
Recruiting
PTK7 Antibody-Drug Conjugate
LY4175408
PRECLINICAL
RET Inhibitor
Selpercatinib
NCT03157128; LIBRETTO-001
2
Active, not recruiting
RET Inhibitor
Selpercatinib
NCT03899792; LIBRETTO-121
2
Active, not recruiting
SMARCA2 (BRM) Inhibitor
LY4050784
NCT06561685
1
Recruiting

Sarcoma

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
CDK4/6 Inhibitor
Abemaciclib
NCT05440786; CAMPFIRE
2
Active, not recruiting
VEGF Receptor-2 Antagonist
Ramucirumab
NCT04145349; CAMPFIRE
2
Active, not recruiting

Thyroid

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
RET Inhibitor
Selpercatinib
NCT03157128; LIBRETTO-001
2
Active, not recruiting
RET Inhibitor
Selpercatinib
NCT04211337; LIBRETTO-531
3
Active, not recruiting